Peter Martus
TMB and BRAF mutation status are independent predictive factors in high-risk melanoma patients with adjuvant anti-PD-1 therapy.
Eckardt J, Schroeder C, Martus P, Armeanu-Ebinger S, Kelemen O, Gschwind A, Bonzheim I, Eigentler T, Amaral T, Ossowski S, Riess O, Flatz L, Garbe C, Forschner A. TMB and BRAF mutation status are independent predictive factors in high-risk melanoma patients with adjuvant anti-PD-1 therapy. J Cancer Res Clin Oncol 2022; 149:833-840.
Feb 22, 2022TMB and BRAF mutation status are independent predictive factors in high-risk melanoma patients with adjuvant anti-PD-1 therapy.
Feb 22, 2022J Cancer Res Clin Oncol 2022; 149:833-840
Eckardt Julia, Schroeder Christopher, Martus Peter, Armeanu-Ebinger Sorin, Kelemen Olga, Gschwind Axel, Bonzheim Irina, Eigentler Thomas Kurt, Amaral Teresa, Ossowski Stephan, Riess Olaf, Flatz Lukas, Garbe Claus, Forschner Andrea
Biomarkers Associated with Immune-Related Adverse Events under Checkpoint Inhibitors in Metastatic Melanoma.
Wölffer M, Battke F, Schulze M, Feldhahn M, Flatz L, Martus P, Forschner A. Biomarkers Associated with Immune-Related Adverse Events under Checkpoint Inhibitors in Metastatic Melanoma. Cancers (Basel) 2022; 14
Jan 8, 2022Biomarkers Associated with Immune-Related Adverse Events under Checkpoint Inhibitors in Metastatic Melanoma.
Jan 8, 2022Cancers (Basel) 2022; 14
Wölffer Marcus, Battke Florian, Schulze Martin, Feldhahn Magdalena, Flatz Lukas, Martus Peter, Forschner Andrea
Association between Immune-Related Adverse Events and Survival in 319 Stage IV Melanoma Patients Treated with PD-1-Based Immunotherapy: An Approach Based on Clinical Chemistry
Serna-Higuita L, Eigentler T, Garbe C, Thomas I, Seeber O, Flatz L, Leiter U, Forschner A, Amaral T, Martus P. Association between Immune-Related Adverse Events and Survival in 319 Stage IV Melanoma Patients Treated with PD-1-Based Immunotherapy: An Approach Based on Clinical Chemistry. Cancers (Basel) 2021; 13
Dec 6, 2021Association between Immune-Related Adverse Events and Survival in 319 Stage IV Melanoma Patients Treated with PD-1-Based Immunotherapy: An Approach Based on Clinical Chemistry
Dec 6, 2021Cancers (Basel) 2021; 13
Serna-Higuita Lina María, Eigentler Thomas Kurt, Garbe Claus, Thomas Ioannis, Seeber Olivia, Flatz Lukas, Leiter Ulrike, Forschner Andrea, Amaral Teresa, Martus Peter
Epidemiology of cutaneous melanoma and keratinocyte cancer in white populations 1943-2036
Garbe C, Leiter U, Flatz L, Martus P, Hollezcek B, Katalinic A, Amaral T, Gandini S, Keim U, Whiteman D. Epidemiology of cutaneous melanoma and keratinocyte cancer in white populations 1943-2036. Eur J Cancer 2021; 152:18-25.
May 29, 2021Epidemiology of cutaneous melanoma and keratinocyte cancer in white populations 1943-2036
May 29, 2021Eur J Cancer 2021; 152:18-25
Garbe Claus, Leiter Ulrike, Flatz Lukas, Martus Peter, Hollezcek Bernd, Katalinic Alexander, Amaral Teresa, Gandini Sara, Keim Ulrike, Whiteman David
ERCP in babies: Low risk of post-ERCP pancreatitis - results from a multicentre survey
Goetz M, Andersen P, Bergman J, Frei N, Schmidt A, Kähler G, Martus P, Dechêne A. ERCP in babies: Low risk of post-ERCP pancreatitis - results from a multicentre survey. United European Gastroenterol J 2019; 8:77-80.
Sep 3, 2019ERCP in babies: Low risk of post-ERCP pancreatitis - results from a multicentre survey
Sep 3, 2019United European Gastroenterol J 2019; 8:77-80
Goetz Martin, Andersen Philipp, Bergman Jacques, Frei Nicola Fabian, Schmidt Arthur, Kähler Georg, Martus Peter, Dechêne Alexander
Randomized phase III study of whole-brain radiotherapy for primary CNS lymphoma
Korfel A, Junghanß C, Birnbaum T, Fischer L, Jahnke K, Herrlinger U, Roth P, Bamberg M, Pietsch T, Mergenthaler H, Hundsberger T, Thiel E, Martus P, Möhle R, Griesinger F, Rauch M, Röth A, Hertenstein B, Fischer T, Weller M. Randomized phase III study of whole-brain radiotherapy for primary CNS lymphoma. Neurology 2015; 84:1242-8.
Feb 25, 2015Randomized phase III study of whole-brain radiotherapy for primary CNS lymphoma
Feb 25, 2015Neurology 2015; 84:1242-8
Korfel Agnieszka, Junghanß Christian, Birnbaum Tobias, Fischer Lars, Jahnke Kristoph, Herrlinger Ulrich, Roth Patrick, Bamberg Michael, Pietsch Torsten, Mergenthaler Hans G, Hundsberger Thomas, Thiel Eckhard, Martus Peter, Möhle Robert, Griesinger Frank, Rauch Michael, Röth Alexander, Hertenstein Bernd, Fischer Thomas, Weller Michael
High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial
Thiel E, Birnbaum T, Fischer L, Jahnke K, Herrlinger U, Plasswilm L, Nägele T, Pietsch T, Bamberg M, Leithäuser M, Mergenthaler H, Hundsberger T, Korfel A, Martus P, Kanz L, Griesinger F, Rauch M, Röth A, Hertenstein B, von Toll T, Weller M. High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial. Lancet Oncol 2010; 11:1036-47.
Oct 20, 2010High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial
Oct 20, 2010Lancet Oncol 2010; 11:1036-47
Thiel Eckhard, Birnbaum Tobias, Fischer Lars, Jahnke Kristoph, Herrlinger Ulrich, Plasswilm Ludwig, Nägele Thomas, Pietsch Torsten, Bamberg Michael, Leithäuser Malte, Mergenthaler Hans-Günther, Hundsberger Thomas, Korfel Agnieszka, Martus Peter, Kanz Lothar, Griesinger Frank, Rauch Michael, Röth Alexander, Hertenstein Bernd, von Toll Theda, Weller Michael
Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin
Berg T, Alshuth U, Martus P, Spengler U, Klinker H, Kallinowski B, Schmidt W, Pape G, Rasenack J, Goeser T, Buggisch P, Gerlach T, Heintges T, Sarrazin C, Nasser S, von Wagner M, Zeuzem S. Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin. Gastroenterology 2006; 130:1086-97.
Apr 1, 2006Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin
Apr 1, 2006Gastroenterology 2006; 130:1086-97
Berg Thomas, Alshuth Ulrich, Martus Peter, Spengler Ulrich, Klinker Hartwig, Kallinowski Birgit, Schmidt Wolfgang E, Pape Gerd R, Rasenack Jens, Goeser Tobias, Buggisch Peter, Gerlach Tilman, Heintges Tobias, Sarrazin Christoph, Nasser Samer, von Wagner Michael, Zeuzem Stefan